ArticlePloS one2026
Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutologous stem cell transplantation remains a cornerstone of treatment for patients with transplant-eligible multiple myeloma (MM). Previous studies using gene expression profiling (GEP) have classified MM into seven molecular subgroups: HY, CD-1, CD-2, LB, PR, MS, and MF. Together with GEP signature, it can help identify patients with better or worse outcomes. In this study, we wanted to study how these molecular subtypes, along with cytogenetics, FISH results, and different treatment regimens, relate to the count of CD34 + hematopoietic progenitor cells (HPC) collected during stem cell mobilization.
methodsWe conducted a retrospective study of 505 MM patients who underwent hematopoietic progenitor cell (HPC) collection between January 2017 and December 2020. Demographic, molecular (FISH, cytogenetics, GEP), clinical, treatment, and mobilization regimen data were collected and analyzed to determine factors influencing CD34 + HPC yield.
resultsFactors associated with reduced CD34 + HPC collection included PR and MF GEP subtypes, deletion 13 (-13), and high-risk genetic classification. In contrast, normal versus abnormal karyotype, hyperdiploid versus hypodiploid karyotype, and the use of either proteasome inhibitors in combination with heterogeneous chemotherapy regimens did not significantly impact CD34 + HPC yield.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.